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Summary.-In vivo growth characteristics of myeloid leukaemia induced by whole-
body irradiation of CBA/H male mice were examined in the strain of origin by
procedures expected to enhance or depress immunological responses. Syngeneic
growth in vivo (survival time and frequency of takes) was not modified by attempted
active immunization with radiation-inactivated cells or by sublethal whole-body
irradiation of recipients before inoculation of small numbers of clonogenic cells.
Since the growth stimuli involved in in vivo repair of severely damaged normal
haemopoietic tissue also did not modify the growth of the radiation-induced leuk-
aemia cells in syngeneic passage, their growth in vivo in the irradiated primary
hosts can be regarded as autonomous by the stage at which leukaemia was diagnosed.
Challenge inocula in the "immunization" experiments were 1-9 clonogenic cells from
4 different passaged lines and in the whole-body radiation experiments, 1-103
clonogenic cells derived from 11 different primary hosts and 4 different passaged
lines.
FOR MORE THAN A DECADE a commonly
held hypothesis underlying the treatment
of malignant disease has been that once
the number of malignant cells in the host
has been sufficiently reduced by active
treatment (surgery, ionizing radiation,
chemical agents) the few remaining viable
cells can and will all be killed by the body's
natural defences, especially its immuno-
logical responses (Denoix & Mathe, 1979).
The prime experimental evidence came
from studies of L1210 leukaemia, a long-
maintained cell line which originated in
methylcholanthrene-treated DBA/2 mice
more than 30 years ago, and was trans-
planted into a compatible hybrid (C57-
BL/6 x DBA/2)F1 (Mathe, 1968; Mathe et
al., 1969). However, the experimental
end-point was primarily prolongation of
survival, not disappearance of the leuk-
aemia, and the demonstration of an
immunological response to L1210 in F1
hybrids between the strain of origin and
other mouse strains (Glynn et al., 1963)
may suggest that the experimental model
was not wholly satisfactory.
Since myeloid leukaemia can be regu-
larly induced in CBA/H male mice by
single brief exposures to X-rays, y-rays
or fission neutrons over a wide range of
doses (Major & Mole, 1978; Mole & Davids,
1980, and unpublished) an alternative
model is available for examining questions
about the survival and behaviour of small
numbers of malignant cells in vivo.
Attempted active "immunization" and
damage to the immune system have been
shown to have no effect, as already noted
(Meldrum & Mole, 1981).
METHODS
CBA/Ca mice have been maintained in this
laboratory by brother-sister mating for over
30 years and will be referred to subsequently
as CBA/H. The diagnosis of myeloid leuk-
aemia was by blood count and film examina-
tion, confirmed by subsequent histological
preparation of tissues. When grafting leuk-
aemia cells, cell smears were made from
another part of the spleen which provided
the cell suspension.
Cell suspensions from spleens of leukaemic
mice were made in Eagle's solution contain-R. A. AIELDRUAI AND R. H. MOLE
ing 2-3% serum from normal male CBA/H
mice. After slicing with scissors or a knife
blade and teasing, a single-cell suspension
was easily prepared by syringing the suspen-
sion through smaller and smaller needles and
then allowing it to stand for a few minutes
to allow clumps of cells to settle. Since it is
characteristic ofmyeloid leukaemia in CBA/H
mice (unlike lymphoid leukaemia) that single
cells in suspension continue to aggregate with
the passage oftime (sometimes quite rapidly),
each stock cell suspension was repeatedly
taken up into a syringe and expelled through
a 25G needle (as used for the i.v. injections)
just before diluting. Each suspension was
similarly treated immediately before it wa.s
injected into mice. For quantitative experi-
ments, 0-2 ml of 10-fold serial dilutions were
injected i.v. each into 5 mice. As a check, the
cell concentration in the dilution intended to
contain 5 x 105 cells/ml was determined in a
haemacytometer.
Maintenance of multiply passaged lines
was usually by i.p. inoculation. If ascitic
fluid began to be evident a single i.v. passage
usually restored the status quo. All recipient
mice were male CBA/H mice 90-110 days
old, except in the experiments involving
active "immunization".
Immunization was attempted by i.v. injec-
tion of 107 freshly prepared spleen cells of a
multi-passaged myeloid leukaemia line which
30-60 min previously had received 30 or
50 Gy 250 kVp X-rays at 8-4 Gy/min in a
plastic container. Three such injections from
succeeding but non-consecutive passages of
a given line were made into male CBA/H
mice, beginning at 60 days of age and then at
intervals of 3-6 weeks. Challenge with small
numbers ofviable leukaemia cells was delayed
until 6-10 weeks after the third immunizing
injection, to avoid possible confusion by
leukaemia originating from cells in the
immunizing injections which had escaped
inactivation by irradiation. At the outset,
before immunization was attempted, pairs of
male mice from 5 litters were selected at
random, one of each pair to be immunized,
the other to be an unimmunized control.
They were challenged with the same cell
inoculum. Because of the time required for
the immunizing procedure, challenge was at
120-160 days of age.
Whole-body irradiation of mice 24 h before
inoculation with living leukaemia cells was
with 250 kVp X-rays at - 0-5 Gy/min.
The viscera of every dead or dying mouse
were examined macroscopically to verify that
leukaemia was grossly evident. The spleen
was enlarged 5-20-fold, uniformly and with-
out circumscribed foci, usually pink or grey-
pink or with brown-green flecks. The liver
was uniformly enlarged, but macroscopically
not obviously infiltrated. Lymph nodes, peri-
pheral and central, and thymus were not
enlarged, except that occasionally cervical
nodes were 2-3-fold normal in size, and
sometimes pale green. The depth of colour of
the sternal marrow and the degree ofanaemia
were variable. In the experiments reported.
there was never anv doubt about the cause of
deaths within 150 days. Later deaths some-
times needed histological study, particularly
when lymphoid leukaemia needed to be
excluded. The macroscopic changes were
evident but much less conspicuous in deaths
following inoculation of cells from multi-
passaged lines.
Mice surviving 300 days after challenge or
at 200 days after the most delayed positive
take, whichever was the later, were killed
and examined to confirm the absence of
leukaemia.
RESULTS
Grafting of myeloid leukaemia cells
Myeloid leukaemia has not been ob-
served in over 500 unirradiated controls
and, apart from grafted cases, has occurred
only in suitably irradiated mice, the
primary hosts. One million or more
myeloid leukaemia cells taken from the
spleen of a freshly killed primary host and
inoculated i.v. have not failed to take in
30 attempts. Even when the spleen cells
were obtained a number of hours after
natural death, the probability of take
seemed to be high. Serial dilution of a
spleen-cell suspension commonly, but not
invariably, gave a linear relationship
between survival time and log (number of
cells injected i.v.) (Figure). This is what
would be predicted from the simplest
possible pair of assumptions, that death
occurs when the number ofleukaemia cells
in the body reaches a given value, in-
dependently of the number injected, and
that after i.v. injection the leukaemia cells
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TABLE II. Influence of whole-body X-irradiation on survival time ofsyngeneic recipients
receiving i.v. inoculations of moderate numbers of cells from the spleen of a CBA/H
male mouse which had developed myeloid leukaemia after whole-body irradiation.*
AMean no.
of cells
injected
105
2-5x 104
104
105
105
Effective AMean survival (days)
cells in
inoculum
(mean)t
1300
?
50
50
30
30
Recipients Recipients
not X-rayed X-rayed:
63 65
60 55
58 59
67 63
59 61
71+4 59+2§
51 54
* Take frequency always 10000.
t Determined from a calibration curve of frequency of takes in groups of syngeneic male CBA/H mice
given 10-fold dilutions of spleen cells. The 95% confidence limits were usually 2-3 x above and below the
mean value.
t Combined observations from mice receiving 2, 4 or 6 Gy X-rays the day before inoculation, except for
XV wvhere the doses were 1-5, 3, 4-5 or 6 Gy.
§ The only statistically establishled difference between X-rayed and unirradiated recipients (P < 0.01).
Attempted immunization by living cells
incapable of clonal division
Mice "immunized" as described with a
given serially passaged line of myeloid
leukaemia cells were challenged by i.v.
injection of 10 unirradiated spleen cells
from a further passage of the same line.
Their non-immunized brothers each re-
ceived 10 cells from the same suspension
on the same occasion. Three further groups
of 5 mice aged 90-110 days were given 1,
10 and 100 cells respectively from the
same cell suspension as a calibration set.
Table I shows that attempted immuniza-
tion had no influence on the frequency of
takes or on the survival time of mice
developing leukaemia, with any of the 4
different lines ofmyeloid leukaemia tested.
The effective number oftruly clonogenic
cells in an inoculum of 10 cells was calcu-
lated from the frequency of leukaemia
takes in the non-immunized mice, and
varied from 0 3 to 9 (Table I).
The dose of 30 Gy to 3 successive
"immunizing" cell suspensions was in-
sufficient to kill every clonogenic cell of 3
of the 4 leukaemia lines. Thus each of the
4 lines was examined using 50 Gy, and
only one (line XVI) with 30 Gy also.
TVhole-body irradiation of recipients
Five male CBA/H mice which had
received 0, 2, 4 or 6 Gy whole-body
X-irradiation the day before were given
the same i.v. injection of unirradiated
spleen cells from leukaemic mice. Cells
from 11 primary hosts and from 3 multiply
passaged lines were used.
Table II gives the survival times of
unirradiated and irradiated mice when the
inoculum from a primary host was more
than sufficient to kill every recipient with
myeloid leukaemia. In 6/7 cases it was
clear that prior irradiation of the recipient
mice had no influence on survival time.
With cells from primary host XIX, the
mean survival time was slightly but
significantly shorter in the irradiated mice.
Table III gives the results of experi-
inents where the frequency of takes was
< 100%. The leukaemia cells came from
4 primary hosts (different from those in
Table II) and from 3 passaged lines (2
derived from primary hosts shown in
Table II). There was no systematic
difference in take frequency between
irradiated and unirradiated recipients.
There was no systematic difference in
survival time in 6/7 experiments. In the
MIyeloid
leukaemia
serial
number
XXI
Ni
N2
XXII
XXVI
XIX
xv
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7th, with passage 7 of line XIX, the
difference in mean survival time between
irradiated and unirradiated recipients
was suggestive (P<0.01). However, sur-
vival time was slightly longer for irradi-
ated recipients, the opposite of what was
observed with a larger effective inoculum
of leukaemia cells from primary host XIX
(Table II).
In 2 of the 4 experiments with minimal
numbers of clonogenic cells from primary
hosts (Table III), the survival time results
were straightforward (XXVII and
XXVIII) but in the other 2, mean sur-
vival time may provide an inadequate
summary. Cells from host XXXI gave an
exceptionally wide range of survival times
for mice developing leukaemia, whether
they had been irradiated or not (Table
III). For XXX cells there were only 3
leukaemia takes for assessment. The
survival time of the unirradiated recipient
at 90 days was much shorter than the 226
and 304 days of the 2 takes in irradiated
recipients (one after 4 Gy, one after 6 Gy).
Overall it seems clear, however, for both
primary and passaged myeloid leukaemia
cells, that whole-body irradiation did not
systematically augment or accelerate the
growth of i.v. injected syngeneic cells,
even when minimum numbers of clono-
genic cells were given.
One methodological problem in inter-
preting delayed takes in recipients irradi-
ated before inoculation is that whole-body
irradiation is itself leukaemogenic.
Amongst over 100 cases of leukaemia so
caused by single brief exposures to
X-rays in the range 1 5-6 Gy, 11 werefound
before 305 days in 759 mice and none
before 226 days. Therefore 2 cases in
15 irradiated recipients of XXX cells at
226 and 304 days are very unlikely to have
been caused by the irradiation. The defi-
nite myeloid leukaemias of arguable
origin in mice receiving XXXI leukaemia
cells were at 383 days after 2 Gy and 460
days after 6 Gy, the next most delayed
being at 202 days after 2 Gy and 195 days
in an unirradiated recipient. This distri-
bution in time, taken at its face value,
could well represent an unusually slowly
developing class of leukaemia cells. How-
ever, if the 2 most delayed cases are dis-
counted as possibly induced by the
irradiation of the recipients (not by the
cells injected), the degree of change in the
results in X-rayed recipients has no bear-
ing on the overall interpretation. Fre-
quency of takes then decreased from 27%
to 13% in X-rayed recipients receiving 0 3
effective cells, and mean survival time
decreased from 136 to 101 + 10 days,
compared with 113 + 16 days in unir-
radiated mice (Table III).
DISCUSSION
There are many reports of occasional
cases of myeloid leukaemia in groups of
laboratory animals treated by a variety of
agents, and presumably induced by them
but, up to the present, systematic and
reproducible induction has been only by
ionizing radiation. The first report (con-
cerning irradiated RF mice), was over 40
years ago, and subsequently extensive
observations were reported by Upton and
his colleagues in the 1950s and 1960s. The
disease closely resembled chronic granu-
locytic leukaemia in man (Upton et al.,
1964). The RF mice were not inbred
(Robinson & Upton, 1978) and grafting of
myeloid leukaemia cells within the strain,
even using very large numbers, was not
always successful, even after 23-27 pas-
sages (Wald et al., 1964). In several
respects, this contrasts with our obser-
vations on highly inbred CBA/H mice, in
which the clinical course and cellular
characteristics resemble acute myeloid
leukaemia, there is a very low level of
the natural disease in unirradiated
controls, and syngeneic grafting is
straightforward.
It is never possible to provide a con-
clusive experimental demonstration of the
absence of a phenomenon. The evidence
presented is the failure to modify the in
vivo growth characteristics of radiation-
induced myeloid leukaemia cells by pro-
cedures which should enhance or depress
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immune responses. Enhancement was
attempted by inoculation oflarge numbers
of cells irradiated to prevent their division
but not so as to produce immediate and
drastic necrosis. Depression of immune
responses was by whole-body irradiation
at about 1 1 or 4 LD50. The testing pro-
cedures were designed to maximize the
chance of demonstrating any natural or
acquired tumour resistance, by using the
smallest possible number of inoculated
clonogenic cells, and were all done in a
syngeneic situation, to minimize the
chances of false positive results. It seems
fair to conclude that if the myeloid
leukaemia cells are immunogenic in vivo,
they are very weakly so.
The failure of prior sublethal whole-
body irradiation to modify the growth
characteristics of the myeloid leukaemia
cells in vivo must also mean that these
cells did not respond to the growth stimuli
responsible for the rapid repair of radia-
tion-damaged normal haemopoietic tissue
which is so characteristic a sequel of sub-
lethal whole-body exposure. Comparison
of irradiated and unirradiated recipients
can be regarded as a test for autonomy of
growth of the inoculated cells. By such a
test the myeloid leukaemia cells used (i.e.,
within a few days of diagnosis in the
primary host) seem truly autonomous. It
remains an open question whether this
autonomy develops progressively during
the "latent interval" between irradiation
and diagnosis or is one aspect ofthe initial
transformation of a postulated haem-
opoietic stem cell into aleukaemia "mother
cell".
An- apparently variable capacity for
growth in a syngeneic host of individual
clonogenic cells from the spleen of a
primary host can be demonstrated, at
least sometimes, when the mean number
of effective clonogenic cells in an injection
volume < 1 (cf. Table III). There could be
a variety of causes, environmental (e.g.
the chance of a single cell arriving in one
micro-environment rather than another in
the injected animal) or intrinsic (e.g.
differences between the genome ofdifferent
cells which can be revealed only when
competition between them can be avoid-
ed). The experiments reported here clearly
throw little light on such questions.
A "natural immune resistance to neo-
plastic tissue elements" has been demon-
strated in many virally and chemically
induced malignancies and in some UV-
induced, but remarkably little has been
published dealing with tumours induced
by ionizing radiation. A large systematic
experiment with radiostrontium-induced
osteosarcomas, using transplantation into
syngeneic recipients previously injected
with large numbers of heavily irradiated
tumour cells and/or given whole-body
irradiation, was interpreted as indicating
specific transplantation antigens in the
osteosarcomas (Nilsson et al., 1972) butthis
interpretation can be questioned. Differ-
ences were not evident over the whole
range of cell inocula, and the basis for the
analysis was a quite unusual postulate for
the relationship between number of
tumour cells inoculated and the take
frequency, based not at all on biological
considerations but simply on a statistical
need for linearity; viz., an arc-sine trans-
formation of the square root of take
frequency against log (cell number).
The evidence provided here about
radiation-induced myeloid leukaemia is
more simply interpretable, and the obser-
vation that a regularly reproducible
radiation-induced malignancy seems not
to be immunogenic may therefore be of
interest. Clearly more examples are re-
quired for confirmation, not only for
myeloid leukaemia but also for other
radiation-induced tumours. Even so, as
they stand, the findings are in close
agreement with the failure to demon-
strate a natural defence mechanism against
spontaneous tumours (Hewitt et al., 1976)
and may be regarded as providing sup-
plementary support for these workers'
conclusion that ". . . practically all the
animal data presented in support of a
general theory of tumour immunogenicity
... have been obtained from transplanted
systems which entail artefactual immunity
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associated with viral or chemical induc-
tion of the tumours or their allogeneic
transplantation".
The intrusion ofallogeneic phenomena is
illustrated in the observations that mye-
loid leukaemia cells originating in the
RFM/UN strain (from Oak Ridge) did not
grow in unirradiated RF mice referred to
as RFJ (from the Jackson Laboratory)
(Husseini et al., 1976) and that they
increased exponentially only for a limited
period in mice referred to as RF/J
(coming from Japan) (Tanaka et al., 1970).
Other reports of the immunogenicity of
myeloid leukaemia cells cannot be fully
assessed becauseofinadequate information
on the genetic compatibility of cells and
the recipients into which they were trans-
planted. No evidence of resistance to
grafts of 106 viable RFM/UN leukaemia
cells was found in RFM/UN mice which
had been given injections of heat-treated
cells of the same origin, but nothing was
said about how the originally non-inbred
mice had been maintained in the decade
before the experiments were done (Adler
& Trobaugh, 1978). If immunogenicity
was detected for the BNML myeloid
leukaemia in Brown Norway rats, it was
very weak (Hagenbeek, 1977) and BNML
is another line ofleukaemia cells which has
been maintained by passage for many
years in different laboratories and used in
animal strains given the same designation
but not necessarily with the same genetic
constitution.
Myeloid leukaemia in a truly inbred
strain of laboratory animal allows less
equivocal experimental investigation of
possible natural defences against very
small numbers of malignant cells ("mini-
mal residual disease") than most experi-
mental models used hitherto. Single-cell
suspensions can be prepared very simply
from primary hosts, allowing quantitative
experiments to be done without the need
for potentially damaging procedures for
tissue disruption, or for preliminary serial
passaging in order to derive cell lines with
reproducible growth characteristics but
with the concomitant and inescapable
selection of only those lines that continue
to grow and only those cells that divide
fastest. No adjuvant procedure is required
to enable small numbers of cells to take.
Results are interpretable without refer-
ence to the development of a blood supply
to a local tumour mass. "Transplantable
animal tumours or long passage in vitro
tumour cell lines may not accurately
reflect the proliferative behaviour of the
small compartment of tumour stem cells
of an individual . . . primary cancer"
(Salmon, 1979). Furthermore, the CBA/H
myeloid leukaemia cells can be maintained
and/or experimented with in vivo in a
truly syngeneic environment (as if they
were continuing to grow in their primary
host) avoiding extraneous and possibly
misleading immunogenetic influences. It is
also easy in practice to use a number of
different primaries in any given investiga-
tion, so improving the validity of any
conclusions that may be drawn.
It is, ofcourse, true that most malignant
disease is in the form of a solid tumour
with a specific blood supply. However, if
it is granted that the only fundamental
difference between myeloid leukaemias
and solid cancers lies in the need, or lack
of it, for a structural component, then
more may be learnt about the specific
properties of the structural component if
an example exists where its influence does
not need to be taken into account when
investigating the properties of malignant
cells as such.
We would like to thank Mr D. G. Papworth for
the computations of the Poisson means and their
confidence limits and the MRC for financial support.
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